Amphastar Pharmaceuticals (NASDAQ:AMPH) Shares Up 3.3% – Here’s Why

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) shares traded up 3.3% on Monday . The company traded as high as $32.16 and last traded at $32.33. 64,789 shares traded hands during trading, a decline of 88% from the average session volume of 521,971 shares. The stock had previously closed at $31.28.

Analyst Upgrades and Downgrades

AMPH has been the subject of several recent research reports. Piper Sandler cut Amphastar Pharmaceuticals from an “overweight” rating to a “neutral” rating and cut their price target for the company from $66.00 to $36.00 in a research note on Tuesday, February 4th. StockNews.com cut shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. Finally, Wells Fargo & Company began coverage on shares of Amphastar Pharmaceuticals in a report on Friday, November 22nd. They issued an “equal weight” rating and a $55.00 price objective for the company. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $50.33.

Amphastar Pharmaceuticals Price Performance

The firm has a market capitalization of $1.55 billion, a P/E ratio of 10.76, a PEG ratio of 2.19 and a beta of 0.81. The company has a fifty day moving average of $35.62 and a 200 day moving average of $42.99. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61.

Insider Activity at Amphastar Pharmaceuticals

In other news, EVP Rong Zhou sold 7,000 shares of the stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $44.42, for a total transaction of $310,940.00. Following the transaction, the executive vice president now owns 118,469 shares of the company’s stock, valued at $5,262,392.98. This represents a 5.58 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Richard K. Prins sold 10,000 shares of the company’s stock in a transaction on Monday, December 9th. The stock was sold at an average price of $43.77, for a total transaction of $437,700.00. Following the transaction, the director now owns 30,471 shares in the company, valued at approximately $1,333,715.67. The trade was a 24.71 % decrease in their position. The disclosure for this sale can be found here. 27.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On Amphastar Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. bought a new stake in Amphastar Pharmaceuticals in the fourth quarter valued at approximately $38,000. Voloridge Investment Management LLC raised its position in shares of Amphastar Pharmaceuticals by 16.2% in the 4th quarter. Voloridge Investment Management LLC now owns 143,436 shares of the company’s stock worth $5,326,000 after purchasing an additional 19,991 shares during the last quarter. Squarepoint Ops LLC increased its holdings in shares of Amphastar Pharmaceuticals by 208.0% in the 4th quarter. Squarepoint Ops LLC now owns 17,664 shares of the company’s stock worth $656,000 after purchasing an additional 11,929 shares in the last quarter. Twinbeech Capital LP purchased a new position in Amphastar Pharmaceuticals in the 4th quarter worth about $1,738,000. Finally, Systematic Financial Management LP bought a new stake in Amphastar Pharmaceuticals in the 4th quarter worth approximately $9,147,000. 65.09% of the stock is currently owned by institutional investors.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.